» Articles » PMID: 25392525

CD4+ T Cell Epitopes of FliC Conserved Between Strains of Burkholderia: Implications for Vaccines Against Melioidosis and Cepacia Complex in Cystic Fibrosis

Abstract

Burkholderia pseudomallei is the causative agent of melioidosis characterized by pneumonia and fatal septicemia and prevalent in Southeast Asia. Related Burkholderia species are strong risk factors of mortality in cystic fibrosis (CF). The B. pseudomallei flagellar protein FliC is strongly seroreactive and vaccination protects challenged mice. We assessed B. pseudomallei FliC peptide binding affinity to multiple HLA class II alleles and then assessed CD4 T cell immunity in HLA class II transgenic mice and in seropositive individuals in Thailand. T cell hybridomas were generated to investigate cross-reactivity between B. pseudomallei and the related Burkholderia species associated with Cepacia Complex CF. B. pseudomallei FliC contained several peptide sequences with ability to bind multiple HLA class II alleles. Several peptides were shown to encompass strong CD4 T cell epitopes in B. pseudomallei-exposed individuals and in HLA transgenic mice. In particular, the p38 epitope is robustly recognized by CD4 T cells of seropositive donors across diverse HLA haplotypes. T cell hybridomas against an immunogenic B. pseudomallei FliC epitope also cross-reacted with orthologous FliC sequences from Burkholderia multivorans and Burkholderia cenocepacia, important pathogens in CF. Epitopes within FliC were accessible for processing and presentation from live or heat-killed bacteria, demonstrating that flagellin enters the HLA class II Ag presentation pathway during infection of macrophages with B. cenocepacia. Collectively, the data support the possibility of incorporating FliC T cell epitopes into vaccination programs targeting both at-risk individuals in B. pseudomallei endemic regions as well as CF patients.

Citing Articles

Novel broadly reactive monoclonal antibody protects against infection.

Mateu-Borras M, Dublin S, Kang J, Monroe H, Sen-Kilic E, Miller S Infect Immun. 2024; 93(1):e0033024.

PMID: 39670709 PMC: 11784295. DOI: 10.1128/iai.00330-24.


Complex Subunit and Glycoconjugate Vaccines and Their Potential to Elicit Cross-Protection to Complex.

Badten A, Torres A Vaccines (Basel). 2024; 12(3).

PMID: 38543947 PMC: 10975474. DOI: 10.3390/vaccines12030313.


Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines.

Khakhum N, Bharaj P, Walker D, Torres A, Endsley J NPJ Vaccines. 2021; 6(1):72.

PMID: 33986290 PMC: 8119421. DOI: 10.1038/s41541-021-00333-4.


Current Advances in Vaccines Development.

Wang G, Zarodkiewicz P, Valvano M Cells. 2020; 9(12).

PMID: 33322641 PMC: 7762980. DOI: 10.3390/cells9122671.


Characterization of the J2315 Surface-Exposed Immunoproteome.

Sousa S, Seixas A, Mandal M, Rodriguez-Ortega M, Leitao J Vaccines (Basel). 2020; 8(3).

PMID: 32899969 PMC: 7565204. DOI: 10.3390/vaccines8030509.


References
1.
Lubamba B, Dhooghe B, Noel S, Leal T . Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem. 2012; 45(15):1132-44. DOI: 10.1016/j.clinbiochem.2012.05.034. View

2.
West T, Chantratita N, Chierakul W, Limmathurotsakul D, Wuthiekanun V, Myers N . Impaired TLR5 functionality is associated with survival in melioidosis. J Immunol. 2013; 190(7):3373-9. PMC: 3607401. DOI: 10.4049/jimmunol.1202974. View

3.
Price E, Sarovich D, Mayo M, Tuanyok A, Drees K, Kaestli M . Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. mBio. 2013; 4(4). PMC: 3735121. DOI: 10.1128/mBio.00388-13. View

4.
Ooi W, Ong C, Nandi T, Kreisberg J, Chua H, Sun G . The condition-dependent transcriptional landscape of Burkholderia pseudomallei. PLoS Genet. 2013; 9(9):e1003795. PMC: 3772027. DOI: 10.1371/journal.pgen.1003795. View

5.
Ascough S, Ingram R, Chu K, Reynolds C, Musson J, Doganay M . Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity. PLoS Pathog. 2014; 10(5):e1004085. PMC: 4006929. DOI: 10.1371/journal.ppat.1004085. View